Lazard Capital Downgrades ViroPharma (VPHM) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts VPHM Hot Sheet
Price: $49.96 --0%
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Join SI Premium – FREE
Lazard Capital downgraded ViroPharma (NASDAQ: VPHM) from Buy to Neutral.
For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.
Shares of ViroPharma closed at $22.44 yesterday.
For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.
Shares of ViroPharma closed at $22.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays cuts Cirrus Logic price target to $95 from $130, cuts to Underweight
- Zelman & Associates Downgrades Real Brokerage Inc. (REAX) to Neutral
- UBS Downgrades Casella Waste Systems (CWST) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
